参考文献/References:
[1]张玉顺,蒋世良,朱鲜阳.卵圆孔未闭相关卒中预防中国专家指南.心脏杂志,2021,33(1):1-10.
[2]Lee M, Oh JH. Echocardiographic diagnosis of righttoleft shunt using transoesophageal and transthoracic echocardiography. Open Heart,2020,7(2):e001150.
[3]Vitarelli A. Patent foramen ovale: Pivotal role of transesophageal echocardiography in the indications for closure, assessment of varying anatomies and postprocedure followup. Ultrasound Med Biol,2019,45(8):1882-1895.
[4]Saric M, Armour AC, Arnaout MS, et al. Guidelines for the use of echocardiography in the evaluation of a cardiac source of embolism. J Am Soc Echocardiogr,2016,29(1):1-42.
[5]Pristipino C, Sievert H, D’Ascenzo F, et al. European Association of Percutaneous Cardiovascular Interventions (EAPCI); European Stroke Organisation (ESO); European Heart Rhythm Association (EHRA); European Association for Cardiovascular Imaging (EACVI); Association for European Paediatric and Congenital Cardiology (AEPC); ESC Working group on GUCH; ESC Working group on Thrombosis; European Haematological Society (EHA). European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention,2019,14(13):1389-1402.
[6]Yuan K, Kasner SE. Patent foramen ovale and cryptogenic stroke: diagnosis and updates in secondary stroke prevention. Stroke Vasc Neurol,2018,3(2):84-91.
[7]赵欣,邓燕.卵圆孔未闭与不明原因脑卒中的研究进展.中华脑血管病杂志（电子版）,2020,14(3):163-166.
[8]Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology,2020,94(20):876-885.
[9]Kent DM, Ruthazer R, Weimar C, et al. An index to identify strokerelated vs incidental patent foramen ovale in cryptogenic stroke. Neurology,2013,81(7):619-625.
[10]Hoda MK, Koziej M. Morphometric features of patent foramen ovale as a risk factor of cerebrovascular accidents: A systematic review and metaanalysis. Cerebrovasc Dis,2020,49(1):1-9.
[11]Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med,2017,377(11):1011-1021.
[12]Sndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med,2017,377 (11):1033-1042.
[13]Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and highrisk patent foramen ovale: The DEFENSEPFO trial. J Am Coll Cardiol,2018,71(20):2335-2342.
[14]Takafuji H, Hosokawa S, Ogura R, et al. Percutaneous transcatheter closure of highrisk patent foramen ovale in the elderly. Heart Vessels,2019,34(10):1657-1662.
[15]Kleber FX, Hauschild T, Schulz A, et al. Epidemiology of myocardial infarction caused by presumed paradoxical embolism via a patent foramen ovale. Circ J,2017,81(10):1484-1489.
[16]Liu K, Wang BZ, Hao Y, et al. The correlation between migraine and patent foramen ovale. Front Neurol,2020,11:543485.
[17]He Q, Zhang Y, Wang F, et al. Impact of righttoleft shunt and transcatheter closure on the clinical features of migraine. Int J Neurosci,2020,130(3):270-275.
[18]Zhang QQ, Lu JJ, Yan MY, et al. The efficacy of percutaneous patent foramen ovale closure on migraine: a metaanalysis of randomized controlled trials and observational studies. Biomed Res Int,2021,2021:6643266.
[19]BenAssa E, RengifoMoreno P, AlBawardy R, et al. Effect of residual interatrial shunt on migraine burden after transcatheter closure of patent foramen ovale. JACC Cardiovasc Interv,2020,13(3):293-302.
[20]Pollock NW, Buteau D. Updates in decompression illness. Emerg Med Clin North Am,2017,35(2):301-319.
[21]Torti SR, Billinger M, Schwerzmann M, et al. Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J,2004,25(12):1014-1020.
[22]Honěk J, rámek M, efc L, et al. Highgrade patent foramen ovale is a risk factor of unprovoked decompression sickness in recreational divers. J Cardiol,2019,74(6):519-523.
[23]Koopsen R, Stella PR, Thijs KM, et al. Persistent foramen ovale closure in divers with a history of decompression sickness. Neth Heart J,2018,26(11):535-539.
[24]Honěk J, rámek M, Honěk T, et al. Patent foramen ovale closure is effective in divers: longterm results from the DIVEPFO registry. J Am Coll Cardiol,2020,76(9):1149-1150.
[25]Pristipino C, Germonpré P, Toni D, et al. European position paper on the management of patients with patent foramen ovale. Part ⅡDecompression sickness, migraine, arterial deoxygenation syndromes and select highrisk clinical conditions. Eur Heart J,2021,42(16):1545-1553.
[26]娄宇轩,华杨,刘翠影,等.卵圆孔未闭与低氧血症研究进展.中国心血管杂志,2021,26(1):89-91.
[27]Barker M, Muthuppalaniappan AM, Abrahamyan L, et al. Periprocedural outcomes of fluoroscopyguided patent foramen ovale closure with selective use of intracardiac echocardiography. Can J Cardiol,2020,36(10):1608-1615.
[28]Horlick E, Kavinsky CJ, Amin Z, et al. SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Catheter Cardiovasc Interv,2019,93(5):859-874.
[29]Moon J, Park Y, Park SJ, et al. Comparison of intracardiac echocardiography and transesophageal echocardiography for image guidance in percutaneous patent foramen ovale closure. Medicina (Kaunas),2020,56(8):401.
[30]Scacciatella P, Meynet I, Giorgi M, et al. Angiography vs transesophageal echocardiographyguided patent foramen ovale closure: A propensity score matched analysis of a twocenter registry. Echocardiography,2018,35(6):834-840.
[31]Han Y, Zhang X, Zhang F. Patent foramen ovale closure by using transesophageal echocardiography for cryptogenic stroke: single center experience in 132 consecutive patients. J Cardiothorac Surg,2020,15(1):11.
[32]Pristipino C, Filice FB. Longterm benefits and risks in patients after persistent foramen ovale closure: a contemporary approach to guide clinical decision making. Kardiol Pol,2021,79(3):248-254.